In a 55-year-old man with mild-to-moderate anxiety who started low-dose fluoxetine 10 mg, can anxiety worsen during the first week due to an overstimulating effect of the medication?

Early Anxiety Worsening with Fluoxetine is a Well-Documented Phenomenon

Yes, fluoxetine can absolutely cause anxiety escalation during the first week of treatment, and this is a recognized adverse effect that does not predict poor treatment response. The FDA explicitly warns that anxiety, agitation, panic attacks, insomnia, irritability, and akathisia can emerge during the initial weeks of SSRI therapy 1.

The Evidence for Early Anxiety Aggravation

The FDA label clearly states that symptoms including anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, and akathisia have been reported in patients being treated with antidepressants during the early phases of treatment 1. This is not limited to any specific indication and occurs across both psychiatric and nonpsychiatric uses.

A 2017 meta-analysis of patient-level data from 8,262 patients provides the most robust evidence: After one week of SSRI treatment, patients were significantly more likely to report enhanced somatic anxiety (9.3% vs 6.7% on placebo) 2. The adverse event "nervousness" was more than twice as common in SSRI-treated patients (5.5% vs 2.5%) 2. Importantly, this early anxiety aggravation did not predict poor antidepressant response 2.

Why This Happens

The mechanism appears related to the "overstimulating" effect you're asking about. Fluoxetine's most common side effects include nausea, anorexia, insomnia, and nervousness 3. These activating properties can be particularly problematic in anxiety-prone patients during the initial treatment phase.

Clinical Management Strategy

For patients with anxiety (especially panic disorder), starting at 5 mg daily rather than the standard 20 mg dose is the evidence-based approach:

• Multiple studies demonstrate that 28% of patients cannot tolerate the full 20 mg dose, with half of these discontinuing entirely 4
• Patients with panic disorder are particularly intolerant of standard dosing 4
• Starting at 5 mg daily and gradually increasing to 20 mg over 1 week significantly improves tolerability 4, 5
• 76% of panic disorder patients achieved moderate to marked improvement when initiated at 5 mg daily 5

Monitoring Requirements

The FDA mandates close monitoring beginning within 1-2 weeks of initiation 1. The American College of Physicians reinforces this, recommending assessment of therapeutic response and adverse effects on a regular basis starting 1-2 weeks after initiation 6.

Watch specifically for:

• Worsening anxiety or agitation
• Emergence of suicidal thoughts (highest risk in first 1-2 months)
• Unusual behavioral changes
• Sleep disturbances
• Physical restlessness (akathisia)

What to Do Now

For your 55-year-old patient experiencing escalating anxiety on 10 mg:

1. This is an expected adverse effect, not treatment failure
2. Consider reducing to 5 mg daily for 1-2 weeks before re-escalating
3. Reassure the patient this typically resolves and doesn't predict poor response
4. If symptoms are severe or intolerable, consider switching to a less activating antidepressant
5. Monitor closely over the next 1-2 weeks

Important Caveat

While early anxiety is common and typically transient, if depression is persistently worsening or emergent suicidality occurs, consider changing the therapeutic regimen or discontinuing the medication 1. The distinction is between transient activation symptoms (which improve) versus true clinical worsening (which persists or escalates).